1.38
+0.02(+1.47%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.37 |
| Day High | 1.44 |
| Day Low | 1.35 |
| 52-Week High | 9.69 |
| 52-Week Low | 1.02 |
| Volume | 189,498 |
| Average Volume | 469,177 |
| Market Cap | 78.1M |
| PE | -1.21 |
| EPS | -1.14 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 3.76 |
| Change | 0.02 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $131.43 as of May 09, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $836.36 as of May 09, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:53 PM GMT
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Mar 31, 2025 11:00 AM GMT
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
GlobeNewswire Inc.
Mar 27, 2025 11:00 AM GMT
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experienceWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the develo